Albumin Market Growth, Size, Share, Demand, Trends and Forecasts to 2026
The global albumin market is likely to gain traction from the rising usage of recombinant DNA technology to safely produce significant proteins and other components in the laboratory setting. This information is given by Fortune Business Insights™ in a recent study, titled, “Albumin Market Size, Share & Industry Analysis, By Product (Human Serum Albumin (HSA), Recombinant Albumin, and Bovine Serum Albumin (BSA)), By Application (Therapeutics, Diagnostics, and Research) By End User (Hospital & Clinics, Pharmaceutical & Biotechnology Industry, and Research Institutes), and Regional Forecast, 2019-2026.” The study further states that the albumin market size was USD 4.29 billion in 2018 and is projected to reach USD 6.77 billion by 2026, exhibiting a CAGR of 6.0% during the forecast period.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/albumin-market-102637
Fortune Business Insights™ lists out some of the most prominent companies operating in the albumin market. They are as follows:
- Kedrion S.p.A
- Octapharma AG
- Biotest AG
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Merck KGaA
- Grifols, S.A
- Seracare Life Sciences
- Novozymes
- Other prominent players
Development of Fractionation Facilities to Skyrocket Demand
Usage of protein is upsurging day by day owing to their possession of several advantages. They are mainly used in the development of crucial drugs. Italy, the U.S., and Belgium, for instance, are exhibiting high demand for protein. It is, in turn, leading to the construction of multiple fractionation facilities for keeping up with the demand and supply balance. These facilities help in fragmenting plasma into albumin and other components. Development of such facilities is aiding the biotechnology and pharmaceutical industries in creating state-of-the-art products for research, diagnostics, and therapeutics applications. However, unavailability of therapeutic products may hinder market growth.
Increasing Sales of Drugs in China to Favor Growth in Asia Pacific
Geographically, the market is segregated into Latin America, the Middle East and Africa, North America, Europe, and Asia Pacific. Asia Pacific generated USD 2.39 billion in 2018 in terms of albumin market revenue. This growth is mainly attributable to the expansion of plasma fractionation facilities, as well as increasing sale of drugs in China. The country is considered to house the largest market because it has imposed high prices on its products. In North America and Europe, the market is likely to experience a comparatively lower CAGR fueled by the availability of drugs and the existence of unique healthcare facilities.
More Trending Topics from Fortune Business Insights:
https://www.fortunebusinessinsights.com/insulin-pump-market-102735
https://www.fortunebusinessinsights.com/automotive-glass-market-102579